October 16, 2012 (Boston, Massachusetts) — Eculizumab, a humanized monoclonal antibody that inhibits cleavage of complement component C5 to active forms, significantly reduced the annual rate of ...

A systematic review found the highest incidence and prevalence of NMO/NMOSD among Caribbean-African populations. Middle-aged adults—those between 40 and 59 years old—had the highest incidence rates of ...

Researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis. The ...

Joanna Robles, MD, first began having unusual symptoms in the summer of 2020. She had bouts of nausea and vomiting that she couldn’t explain. Eventually doctors diagnosed her with neuromyelitis optica ...

A rare case describes onset of myasthenia gravis, neuromyelitis optica, and anti-N-methyl-D-aspartate receptor in one woman, ...

Please provide your email address to receive an email when new articles are posted on . In a company release, Horizon Therapeutics announced results from a phase 2/3 trial demonstrating that its ...

The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). This rare but severe ...

New data further support satralizumab as a potential treatment option for NMOSD, a rare, debilitating condition with few approved treatment options Basel, 22 May 2020 - Roche (SIX: RO, ROG; OTCQX: ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

The treatment of neuromyelitis optica spectrum disorder (NMOSD) has transformed in recent years with new options for a disease that has typically resulted in vision loss, paralysis, and early death.

A nonpathogenic monoclonal antibody might hold the key to successful treatment of neuromyelitis optica (NMO)—an autoimmune demyelinating disease characterized by lesions in the optic nerve and spinal ...